Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Repeat-Dose Toxicity Study of a Lyophilized Recombinant Protective Antigen-Based Anthrax Vaccine Adjuvanted With CpG 7909.

Savransky V, Lacy M, Ionin B, Skiadopoulos MH, Shearer J.

Int J Toxicol. 2019 May/Jun;38(3):163-172. doi: 10.1177/1091581819848722.

PMID:
31179828
2.

Efficacy of atropine sulfate/obidoxime chloride co-formulation against sarin exposure in guinea pigs.

Joosen MJA, Klaassen SD, Verheij E, van Groningen T, Cornelissen AS, Skiadopoulos MH, Cochrane L, Shearer JD.

Chem Biol Interact. 2018 Dec 25;296:34-42. doi: 10.1016/j.cbi.2018.09.004. Epub 2018 Sep 12.

PMID:
30217478
3.

Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Savransky V, Shearer JD, Gainey MR, Sanford DC, Sivko GS, Stark GV, Li N, Ionin B, Lacy MJ, Skiadopoulos MH.

Vaccine. 2017 Sep 5;35(37):4952-4959. doi: 10.1016/j.vaccine.2017.07.076. Epub 2017 Jul 31.

4.

Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule.

Longstreth J, Skiadopoulos MH, Hopkins RJ.

Expert Rev Vaccines. 2016 Dec;15(12):1467-1479. Review.

PMID:
27792416
5.

Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans.

Malkevich NV, Hopkins RJ, Bernton E, Meister GT, Vela EM, Atiee G, Johnson V, Nabors GS, Aimes RT, Ionin B, Skiadopoulos MH.

Antimicrob Agents Chemother. 2014 Jul;58(7):3618-25. doi: 10.1128/AAC.02295-13. Epub 2014 Apr 14.

6.

Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits.

Malkevich NV, Basu S, Rudge TL Jr, Clement KH, Chakrabarti AC, Aimes RT, Nabors GS, Skiadopoulos MH, Ionin B.

Antimicrob Agents Chemother. 2013 Nov;57(11):5693-6. doi: 10.1128/AAC.00460-13. Epub 2013 Aug 26.

7.

Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.

Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH.

Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. doi: 10.1128/AAC.00458-13. Epub 2013 Aug 26.

8.

Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, Rudge TL Jr, Stark GV, Innes A, Sari S, Guina T, Howard C, Smith J, Swoboda ML, Vert-Wong E, Johnson V, Nabors GS, Skiadopoulos MH.

Clin Vaccine Immunol. 2013 Jul;20(7):1016-26. doi: 10.1128/CVI.00099-13. Epub 2013 May 8.

9.

Pathology and pathophysiology of inhalational anthrax in a guinea pig model.

Savransky V, Sanford DC, Syar E, Austin JL, Tordoff KP, Anderson MS, Stark GV, Barnewall RE, Briscoe CM, Lemiale-Biérinx L, Park S, Ionin B, Skiadopoulos MH.

Infect Immun. 2013 Apr;81(4):1152-63. doi: 10.1128/IAI.01289-12. Epub 2013 Jan 28.

10.

Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.

Schaap-Nutt A, D'Angelo C, Amaro-Carambot E, Nolan SM, Davis S, Wise SM, Higgins C, Bradley K, Kim O, Mayor R, Skiadopoulos MH, Collins PL, Murphy BR, Schmidt AC.

Virology. 2010 Oct 10;406(1):65-79. doi: 10.1016/j.virol.2010.07.011. Epub 2010 Jul 27.

11.

A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

Bartlett EJ, Cruz AM, Boonyaratanakornkit J, Esker J, Castaño A, Skiadopoulos MH, Collins PL, Murphy BR, Schmidt AC.

Vaccine. 2010 Jan 8;28(3):767-79. doi: 10.1016/j.vaccine.2009.10.069. Epub 2009 Oct 24.

12.

CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Zhang L, Button B, Gabriel SE, Burkett S, Yan Y, Skiadopoulos MH, Dang YL, Vogel LN, McKay T, Mengos A, Boucher RC, Collins PL, Pickles RJ.

PLoS Biol. 2009 Jul;7(7):e1000155. doi: 10.1371/journal.pbio.1000155. Epub 2009 Jul 21.

13.

Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.

Bartlett EJ, Hennessey M, Skiadopoulos MH, Schmidt AC, Collins PL, Murphy BR, Pickles RJ.

J Virol. 2008 Aug;82(16):8059-70. doi: 10.1128/JVI.02263-07. Epub 2008 Jun 4.

14.

Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro-Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL, Murphy BR, Schaap-Nutt A.

Vaccine. 2007 Aug 21;25(34):6409-22. Epub 2007 Jul 3.

15.
16.

An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.

Surman SR, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol Methods. 2007 Apr;141(1):30-3. Epub 2007 Jan 8.

PMID:
17210187
17.

Nonsegmented negative-strand viruses as vaccine vectors.

Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL.

J Virol. 2006 Nov;80(21):10293-306. Review. No abstract available.

18.

Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.

Van Cleve W, Amaro-Carambot E, Surman SR, Bekisz J, Collins PL, Zoon KC, Murphy BR, Skiadopoulos MH, Bartlett EJ.

Virology. 2006 Aug 15;352(1):61-73. Epub 2006 Jun 5.

20.

Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.

Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH.

Vaccine. 2006 Mar 24;24(14):2674-84. Epub 2005 Nov 15.

PMID:
16364511
22.

Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.

Skiadopoulos MH, Biacchesi S, Buchholz UJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR.

Virology. 2006 Feb 20;345(2):492-501. Epub 2005 Nov 21.

24.
25.

Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression.

Biacchesi S, Skiadopoulos MH, Yang L, Murphy BR, Collins PL, Buchholz UJ.

J Virol Methods. 2005 Sep;128(1-2):192-7.

PMID:
15955576
26.

Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.

Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH.

Vaccine. 2005 Sep 7;23(38):4631-46.

PMID:
15951066
27.

Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity.

Buchholz UJ, Biacchesi S, Pham QN, Tran KC, Yang L, Luongo CL, Skiadopoulos MH, Murphy BR, Collins PL.

J Virol. 2005 Jun;79(11):6588-97.

28.

Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate.

Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, Collins PL, Buchholz UJ.

J Virol. 2004 Dec;78(23):12877-87.

29.

The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, McAuliffe JM, Elkins WR, St Claire M, Collins PL, Murphy BR.

J Virol. 2004 Jul;78(13):6927-37.

30.

Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes.

Biacchesi S, Skiadopoulos MH, Tran KC, Murphy BR, Collins PL, Buchholz UJ.

Virology. 2004 Apr 10;321(2):247-59.

32.

Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Newman JT, Riggs JM, Surman SR, McAuliffe JM, Mulaikal TA, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol. 2004 Feb;78(4):2017-28.

33.

Genetic diversity between human metapneumovirus subgroups.

Biacchesi S, Skiadopoulos MH, Boivin G, Hanson CT, Murphy BR, Collins PL, Buchholz UJ.

Virology. 2003 Oct 10;315(1):1-9.

34.

Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.

Skiadopoulos MH, Schmidt AC, Riggs JM, Surman SR, Elkins WR, St Claire M, Collins PL, Murphy BR.

J Virol. 2003 Jan;77(2):1141-8.

35.

More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Bukreyev A, Skiadopoulos MH, McAuliffe J, Murphy BR, Collins PL, Schmidt AC.

Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16987-91. Epub 2002 Dec 13.

37.

Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.

Skiadopoulos MH, Surman SR, Riggs JM, Elkins WR, St Claire M, Nishio M, Garcin D, Kolakofsky D, Collins PL, Murphy BR.

Virology. 2002 May 25;297(1):153-60.

38.

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.

Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR.

Virology. 2002 May 25;297(1):136-52.

39.

Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.

Newman JT, Surman SR, Riggs JM, Hansen CT, Collins PL, Murphy BR, Skiadopoulos MH.

Virus Genes. 2002;24(1):77-92. Erratum in: Virus Genes. 2003 Jan;26(1):107.

PMID:
11928991
40.

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.

Skiadopoulos MH, Tatem JM, Surman SR, Mitcho Y, Wu SL, Elkins WR, Murphy BR.

Vaccine. 2002 Mar 15;20(13-14):1846-52.

PMID:
11906774
41.
42.

Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.

Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR.

Vaccine. 2001 Jun 14;19(27):3620-31.

PMID:
11395195
43.

Comparison of identical temperature-sensitive mutations in the L polymerase proteins of sendai and parainfluenza3 viruses.

Feller JA, Smallwood S, Skiadopoulos MH, Murphy BR, Moyer SA.

Virology. 2000 Oct 10;276(1):190-201.

44.

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.

Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol. 2000 Oct;74(19):8922-9.

45.
46.
47.

Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.

Bailly JE, McAuliffe JM, Skiadopoulos MH, Collins PL, Murphy BR.

Virus Genes. 2000;20(2):173-82.

PMID:
10872880
50.

Supplemental Content

Loading ...
Support Center